Insider Trading May 19, 2026 04:41 PM

Hanover Insurance CEO Sells Stock Following Option Exercise Amid Mixed Market Signals

Analysis of recent insider transactions and contrasting analyst ratings for THG following strong Q1 results.

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
THG

John C. Roche, President and CEO of Hanover Insurance Group, Inc., sold a significant block of company stock after exercising vested options. This activity occurs while the stock is trading near its 52-week high, set against a backdrop of mixed analyst sentiment and recent positive financial disclosures from the company.

Hanover Insurance CEO Sells Stock Following Option Exercise Amid Mixed Market Signals
THG
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • The sale of stock by CEO John C. Roche occurred under a pre-established Rule 10b5-1 trading plan.
  • Hanover Insurance recently reported strong first-quarter earnings and revenue, surpassing analyst expectations.
  • Analyst coverage is mixed, with some firms raising price targets while others cite valuation concerns.

John C. Roche, President and CEO of Hanover Insurance Group, Inc. (NASDAQ:THG), executed a sale of shares on May 18, 2026. Specifically, Mr. Roche sold 5,251 shares of the company's common stock, generating total proceeds valued at $1,040,031.

The selling activity was conducted across several price points, with individual transactions ranging from $196.07 to $199.23 per share. Notably, these sales were carried out pursuant to a pre-established trading plan, designated as Rule 10b5-1, which had been adopted by Mr. Roche on November 19, 2025.


The timing of this transaction is noteworthy given the current market positioning of THG stock. The company's shares are currently priced at $193.79, placing them near their 52-week high of $199.59. Further analysis from InvestingPro suggests that the stock may be overvalued when compared to its calculated Fair Value, leading to its inclusion in the list of companies deemed 'Most Overvalued.'


The recent sales followed a larger corporate action: the exercise of options for 18,194 shares of common stock on May 15, 2026. The total value of these exercised options amounted to $1,562,318, based on an exercise price of $85.87 per share.

As part of the required

Risks

  • The stock may be overvalued relative to its Fair Value, according to InvestingPro analysis.
  • BMO Capital downgraded the stock to Market Perform from Outperform due to valuation concerns (trading at approximately 1.8 times book value).
  • The company's previous buyback program had concluded, though a new one was approved.

More from Insider Trading

Cardiff Oncology CEO Mani Mohindru Acquires $49,999 in Stock and Warrants Amid Market Volatility Jul 16, 2026 Semtech COO Executes $435,120 Stock Sale via Pre-Arranged Plan Jul 16, 2026 Nextdoor Product Executive Lisowski Offloads Shares Under Pre-Arranged Plan Jul 16, 2026 M&T Bank Vice Chairman Pearson Executes Pre-Arranged Share Sale Jul 16, 2026 FB Financial Corp Chief Accounting Officer Executes $413K Share Disposition Jul 16, 2026